The two patient populations most likely to respond completely to NAST are those with HER2-positive disease receiving dual anti-HER2 targeting and triple-negative breast cancer (TNBC) receiving immunotherapy, which has been shown to increase the rate of pCR and ypN0 [1,6]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.